
Vaibhavi M. | Dec 06, 2025

Ravindra Warang | Jun 23, 2025
Key challenges reshaping pharmaceutical manufacturing in 2026 and the strategic opportunities emerging from them.
20260213185438.webp)
Top global companies advancing mRNA therapeutics in 2026, from vaccines to cancer immunotherapy and rare disease treatments.
20260109114026.webp)
Pharmaceutical contract manufacturing in 2026 evolves as CDMOs become strategic partners driving scale, compliance, and innovation.

Explore how mRNA therapeutics are manufactured, from DNA templates to LNP formulation, with key challenges, regulations, and future trends.

Vaccine contract manufacturing in 2026 shifts toward digitalization, regionalization, and strategic CDMO partnerships powering global immunization
